Last reviewed · How we verify
NCT05785819
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
Phase 2 trial testing VLX-1005 in Thrombocytopenia, Immune in 24 participants. Terminated before completion.
17 November 2025
Quick facts
| Lead sponsor | Veralox Therapeutics |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 26 September 2023 |
| Primary completion | 17 November 2025 |
| Estimated completion | 17 November 2025 |
| Sites | 14 locations across United States |
Drugs / interventions tested
- VLX-1005 — full drug profile →
- Placebo
Conditions studied
- Thrombocytopenia, Immune — all drugs for Thrombocytopenia, Immune →
- Heparin Induced Thrombocytopenia — all drugs for Heparin Induced Thrombocytopenia →
Sponsor
Veralox Therapeutics
Who can join
18 and older, any sex, with Thrombocytopenia, Immune or Heparin Induced Thrombocytopenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT). Participants with suspected HIT will receive the usual standard of care, and will be assigned randomly to either VLX-1005 or placebo treatment. The study will measure important outcomes including platelet count, stroke, pulmonary embolus (clot to the lungs) and bleeding.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Inhibition of ALOX12-12-HETE Alleviates Lung Ischemia-Reperfusion Injury by Reducing Endothelial Ferroptosis-Mediated Neutrophil Extracellular Trap Formation.
Li C, Gao P, Zhuang F, Wang T, et al · · 2024 · cited 25× · PMID 39268501 · DOI 10.34133/research.0473 -
Practical guide to the diagnosis and management of heparin-induced thrombocytopenia.
May J, Cuker A. · · 2024 · cited 4× · PMID 39644042 · DOI 10.1182/hematology.2024000566 -
VLX-1005, but not argatroban, prevents ITAM-mediated platelet activation and heparin-induced thrombocytopenia.
Yamaguchi A, Putzbach V, Adili R, Lazar S, et al · · 2026 · PMID 41909515 · DOI 10.1016/j.bvth.2026.100146
Verify or expand the search:
- PubMed search for NCT05785819
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of VLX-1005
Trials testing the same drug.
- NCT05325346 — A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects · Phase 1 · completed
- NCT04783545 — Phase I Study of VLX-1005 in Healthy Subjects · Phase 1 · completed
Other Veralox Therapeutics trials
Trials by the same sponsor.
- NCT05325346 — A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects · Phase 1 · completed
- NCT04783545 — Phase I Study of VLX-1005 in Healthy Subjects · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05785819 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Veralox Therapeutics
- Last refreshed: 25 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05785819.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing